Real-world safety profile of resmetirom for metabolic dysfunction-associated steatohepatitis: a disproportionality analysis of FAERS reports

Background Resmetirom is the first FDA-approved medication for metabolic dysfunction-associated steatohepatitis (MASH). This study aimed to characterize adverse event reporting for resmetirom in the FDA Adverse Event Reporting System (FAERS) and assess whether safety signals persisted against a metabolic disease reporting background. Methods We analyzed FAERS reports identifying resmetirom as the primary suspect drug from 2024Q1 to 2026Q2. Reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and empirical Bayes geometric mean (EBGM) were calculated against the full-database and metabolic disease reporting backgrounds. Additional analyses examined report-level time-to-onset (TTO), recorded serious outcomes, and co-reported medications. Results We identified 1,725 resmetirom reports containing 5,187 distinct report-preferred term (PT) pairs. Disproportionality analysis yielded 56 and 50 PTs that met the signal detection criteria against the full-database and metabolic disease backgrounds, respectively. Hepatobiliary disorders and aminotransferase elevations met the signal criteria in both comparisons. Reports containing hepatic laboratory terms more often had recorded serious outcomes than reports containing common gastrointestinal symptoms. Among 207 reports with evaluable TTO (12.0%), the median was 14 days and 65.2% had a reported onset within 30 days. Co-reported medications included the statin atorvastatin, which was listed in 9.5% of resmetirom reports, and the incretin-based therapies semaglutide and tirzepatide, which were listed in 5.0% and 4.2% of reports, respectively. Exploratory analyses suggested a reporting interaction between resmetirom and statins for liver enzyme elevations. Conclusions Hepatobiliary reporting signals persisted across the two comparator backgrounds. These signals and the exploratory statin finding warrant further evaluation in data that can characterize baseline liver disease and verify treatment exposure.

Authors

Institutions

Publication Details

Journal
Egyptian Liver Journal
Published
2026-11-19
DOI
https://doi.org/10.1186/s43066-026-00577-6
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-world safety profile of resmetirom for metabolic dysfunction-associated steatohepatitis: a disproportionality analysis of FAERS reports

Gong Panpan, Peipei Liu, Yin Huang
Egyptian Liver Journal
Pharmacovigilance and Adverse Drug Reactions
article

Real-world safety profile of resmetirom for metabolic dysfunction-associated steatohepatitis: a disproportionality analysis of FAERS reports

Gong Panpan, Peipei Liu, Yin Huang
article en

Abstract

Background Resmetirom is the first FDA-approved medication for metabolic dysfunction-associated steatohepatitis (MASH). This study aimed to characterize adverse event reporting for resmetirom in the FDA Adverse Event Reporting System (FAERS) and assess whether safety signals persisted against a metabolic disease reporting background. Methods We analyzed FAERS reports identifying resmetirom as the primary suspect drug from 2024Q1 to 2026Q2. Reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and empirical Bayes geometric mean (EBGM) were calculated against the full-database and metabolic disease reporting backgrounds. Additional analyses examined report-level time-to-onset (TTO), recorded serious outcomes, and co-reported medications. Results We identified 1,725 resmetirom reports containing 5,187 distinct report-preferred term (PT) pairs. Disproportionality analysis yielded 56 and 50 PTs that met the signal detection criteria against the full-database and metabolic disease backgrounds, respectively. Hepatobiliary disorders and aminotransferase elevations met the signal criteria in both comparisons. Reports containing hepatic laboratory terms more often had recorded serious outcomes than reports containing common gastrointestinal symptoms. Among 207 reports with evaluable TTO (12.0%), the median was 14 days and 65.2% had a reported onset within 30 days. Co-reported medications included the statin atorvastatin, which was listed in 9.5% of resmetirom reports, and the incretin-based therapies semaglutide and tirzepatide, which were listed in 5.0% and 4.2% of reports, respectively. Exploratory analyses suggested a reporting interaction between resmetirom and statins for liver enzyme elevations. Conclusions Hepatobiliary reporting signals persisted across the two comparator backgrounds. These signals and the exploratory statin finding warrant further evaluation in data that can characterize baseline liver disease and verify treatment exposure.

Egyptian Liver JournalVol. 16(1)
China Pharmaceutical University (CN), Anhui Xinhua University (CN)
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon